1921
Volume 96, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Large protracted outbreaks of hepatitis E virus (HEV) have been documented in displaced populations in Africa over the past decade though data are limited outside these exceptional settings. Serological studies can provide insights useful for improving surveillance and disease control. We conducted an age-stratified serological survey using samples previously collected for another research study from 206 residents of an internally displaced person camp in Juba, South Sudan. We tested serum for anti-HEV antibodies (IgM and IgG) and estimated the prevalence of recent and historical exposure to the virus. Using data on individuals' serostatus, camp arrival date, and state of origin, we used catalytic transmission models to estimate the relative risk of HEV infection in the camp compared with that in the participants' home states. The age-adjusted seroprevalence of anti-HEV IgG was 71% (95% confidence interval = 63–78), and 4% had evidence of recent exposure (IgM). We estimated HEV exposure rates to be more than 2-fold (hazard ratio = 2.3, 95% credible interval = 0.3–5.8) higher in the camp than in the participants' home states, although this difference was not statistically significant. HEV transmission may be higher than previously appreciated, even in the absence of reported cases. Improved surveillance in similar settings is needed to understand the burden of disease and minimize epidemic impact through early detection and response.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0620
2017-06-07
2017-06-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/6/1296.html?itemId=/content/journals/10.4269/ajtmh.16-0620&mimeType=html&fmt=ahah

References

  1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA, , 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 20952128.[Crossref]
  2. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST, , 2012. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55: 988997.[Crossref]
  3. Gurley ES, Halder AK, Streatfield PK, Sazzad HM, Huda TM, Hossain MJ, Luby SP, , 2012. Estimating the burden of maternal and neonatal deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection. Am J Public Health 102: 22482254.[Crossref]
  4. Shah R, Nahar Q, Gurley ES, , 2016. One in five maternal deaths in Bangladesh associated with acute jaundice: results from a National Maternal Mortality Survey. Am J Trop Med Hyg 94: 695697.[Crossref]
  5. Teshale EH, Howard CM, Grytdal SP, Handzel TR, Barry V, Kamili S, Drobeniuc J, Okware S, Downing R, Tappero JW, Bakamutumaho B, Teo CG, Ward JW, Holmberg SD, Hu DJ, , 2010. Hepatitis E epidemic, Uganda. Emerg Infect Dis 16: 126129.[Crossref]
  6. Centers for Disease Control and Prevention (CDC), 2013. Investigation of hepatitis E outbreak among refugees: Upper Nile, South Sudan, 2012–2013. Morb Mortal Wkly Rep 62: 581586.
  7. Guthmann J-P, Klovstad H, Boccia D, Hamid N, Pinoges L, Nizou JY, Tatay M, Diaz F, Moren A, Grais RF, Ciglenecki I, Nicand E, Guerin PJ, , 2006. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis 42: 16851691.[Crossref]
  8. Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS, , 2010. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376: 895902.[Crossref]
  9. World Health Organization, 2015. Hepatitis E vaccine: WHO position paper. Wkly Epidemiol Rec 90: 185200.
  10. Boccia D, Guthmann J-P, Klovstad H, Hamid N, Tatay M, Ciglenecki I, Nizou JY, Nicand E, Guerin PJ, , 2006. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis 42: 16791684.[Crossref]
  11. Browne LB, Menkir Z, Kahi V, Maina G, Asnakew S, Tubman M, Elyas HZ, Nigatu A, Dak D, Maung UA, Nakao JH, Bilukha O, Shahpar C, Centers for Disease Control and Prevention (CDC), , 2015. Notes from the field: hepatitis E outbreak among refugees from South Sudan: Gambella, Ethiopia, April 2014–January 2015. Morb Mortal Wkly Rep 64: 537.
  12. Phillips RM, Vujcic J, Boscoe A, Handzel T, Aninyasi M, Cookson ST, Blanton C, Blum L, Ram PK, , 2015. Soap is not enough: handwashing practices and knowledge in refugee camps, Maban County, South Sudan. Confl Health 9: 39.[Crossref]
  13. Siddiqui R, , 2015. South Sudan, Health Risks Increasing for People in Bentiu Protection of Civilian Camp. Geneva, Switzerland: Médecins Sans Frontières (MSF) International. Available at: http://www.msf.org/article/south-sudan-health-risks-increasing-people-bentiu-protection-civilian-camp. Accessed April 11, 2016.
  14. Iyer AS, Bouhenia M, Rumunu J, Abubakar A, Gruninger RJ, Pita J, Lino RL, Deng LL, Wamala JF, Ryan ET, Martin S, Legros D, Lessler J, Sack DA, Luquero FJ, Leung DT, Azman AS, , 2016. Immune responses to an oral cholera vaccine in internally displaced persons in South Sudan. Sci Rep 6: 35742.[Crossref]
  15. CCCM Cluster, 2015. UN House PoC 3 Site Profile: June 2015. Available at: http://www.reachresourcecentre.info/system/files/resource-documents/reach_camp_sdd_factsheet_jubapoc3_june2015_8.pdf. Accessed June 3, 2016.
  16. Lumley T, , 2004. Analysis of complex survey samples. J Stat Softw 9.[Crossref]
  17. Agresti A, , 2013. Categorical Data Analysis, 3rd edition. Hoboken, NJ: Wiley.
  18. Anderson RM, May RM, , 1992. Infectious Diseases of Humans: Dynamics and Control. Oxford, United Kingdom: Oxford University Press.
  19. Salje H, Cauchemez S, Alera MT, Rodriguez-Barraquer I, Thaisomboonsuk B, Srikiatkhachorn A, Lago CB, Villa D, Klungthong C, Tac-An IA, Fernandez S, Velasco JM, Roque VG, Jr Nisalak A, Macareo LR, Levy JW, Cummings D, Yoon IK, , 2016. Reconstruction of 60 years of chikungunya epidemiology in the Philippines demonstrates episodic and focal transmission. J Infect Dis 213: 604610.[Crossref]
  20. Imai N, Dorigatti I, Cauchemez S, Ferguson NM, , 2015. Estimating dengue transmission intensity from sero prevalence surveys in multiple countries. PLoS Negl Trop Dis 9: e0003719.[Crossref]
  21. McCarthy MC, He J, Hyams KC, el Tigani A, Khalid IO, Carl M, , 1994. Acute hepatitis E infection during the 1988 floods in Khartoum, Sudan. Trans R Soc Trop Med Hyg 88: 177.[Crossref]
  22. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB, , 2013. Bayesian Data Analysis, 3rd edition. Boca Raton, FL: CRC Press.
  23. Kim J-H, Jong-Hoon K, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF, , 2014. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infect Dis 14: 308.[Crossref]
  24. Izopet J, Labrique AB, Basnyat B, Dalton HR, Kmush B, Heaney CD, Nelson KE, Ahmed ZB, Zaman K, Mansuy JM, Bendall R, Sauné K, Kamar N, Arjyal A, Karkey A, Dongol S, Prajapati KG, Adhikary D, , 2015. Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France. J Clin Virol 70: 3942.[Crossref]
  25. Zhang J, Zhang X-F, Zhou C, Wang ZZ, Huang SJ, Yao X, Liang ZL, Wu T, Li JX, Yan Q, Yang CL, Jiang HM, Huang HJ, Xian YL, Shih JW, Ng MH, Li YM, Wang JZ, Zhu FC, Xia NS, , 2014. Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity. Clin Microbiol Infect 20: O397O405.[Crossref]
  26. Koshy A, Grover S, Hyams KC, Shabrawy MA, Pacsa A, al-Nakib B, Zaidi SA, al-Anezi AA, al-Mufti S, Burans J, Carl M, Richards AL, , 1996. Short-term IgM and IgG antibody responses to hepatitis E virus infection. Scand J Infect Dis 28: 439441.[Crossref]
  27. Favorov MO, Fields HA, Purdy MA, Yashina TL, Aleksandrov AG, Alter MJ, Yarasheva DM, Bradley DW, Margolis HS, , 1992. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. J Med Virol 36: 246250.[Crossref]
  28. Favorov MO, Khudyakov YE, Mast EE, Yashina TL, Shapiro CN, Khudyakova NS, Jue DL, Onischenko GG, Margolis HS, Fields HA, , 1996. IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein. J Med Virol 50: 5058.[Crossref]
  29. Pas SD, Streefkerk RHRA, Pronk M, de Man RA, Beersma MF, Osterhaus AD, van der Eijk AA, , 2013. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol 58: 629634.[Crossref]
  30. Hoofnagle JH, Nelson KE, Purcell RH, , 2012. Hepatitis E. N Engl J Med 367: 12371244.[Crossref]
  31. Zhang J, Zhang X-F, Huang S-J, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JW, Ng MH, Zhu FC, Xia NS, , 2015. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372: 914922.[Crossref]
  32. Wickham H, , 2009. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0620
Loading
/content/journals/10.4269/ajtmh.16-0620
Loading

Data & Media loading...

Supplementary Data

Supplemental Tables and Figures

  • Received : 31 Jul 2016
  • Accepted : 26 Dec 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error